The Effects of Degenerative Mitral Regurgitation on Cardiac Structure and Function, Symptoms, and Exercise Capacity
Study Overview
Status
Status
Conditions
Conditions
Detailed Description
Study Type
Study Type
Enrollment (Anticipated)
Enrollment
Contacts and Locations
Study Contact
Study Contact
- Name: SETH URETSKY, MD
- Phone Number: 9739715597
- Email: seth.uretsky@atlantichealth.com
Study Locations
-
-
New Jersey
-
Morristown, New Jersey, United States, 07960
- Recruiting
- Morristown Medical Center
-
Contact:
- Seth Uretsky, MD
- Phone Number: 973-971-5597
- Email: seth.uretsky@atlantichealth.org
-
Contact:
- Susan Miller, RN
- Phone Number: 9739715597
- Email: susan.miller@atlantichealth.org
-
Principal Investigator:
- Seth Uretsky, MD
-
-
Participation Criteria
Eligibility Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Genders Eligible for Study
Sampling Method
Study Population
Description
Inclusion Criteria:
- Age >=18 yrs
- able to give informed consent
- Diagnoses of moderate or severe degenerative mitral regurgitation (based on the integrated approach recommended by the American Society of Echocardiography)
Exclusion Criteria:
- Left ventricular ejection fraction <60%
- Heart failure
- Pulmonary hypertension (pulmonary artery systolic pressure >40mmHg at rest or >60mmHg with exercise as assessed by echocardiography)
- Atrial fibrillation
- Concomitant > mild aortic or mitral stenosis, >mild aortic or tricuspid or pulmonic regurgitation
- Prior valvular heart disease surgery
- Hypertrophic cardiomyopathy or an infiltrative cardiomyopathy
- Unable to exercise on a treadmill
- Symptomatic coronary artery disease
- Comorbidities expected to impact functional capacity and confound symptom assessment (e.g COPD)
- Expected lifespan of less than 2 years
Study Plan
How is the study designed?
Design Details
What is the study measuring?
Primary Outcome Measures
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
|---|---|---|
|
Change in mitral regurgitant volume
Time Frame: Entry into study, 1 year, and 2 years
|
Change in mitral regurgitant volume quantified by MRI over follow-up period
|
Entry into study, 1 year, and 2 years
|
Secondary Outcome Measures
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
|---|---|---|
|
Change in left ventricular end-diastolic volume
Time Frame: Entry into study, 1 year, and 2 years
|
Change in left ventricular end-diastolic volume quantified by MRI over follow-up period
|
Entry into study, 1 year, and 2 years
|
|
Change in symptoms and quality
Time Frame: Entry into study, 1 year, and 2 years
|
Change in symptoms and quality of life as measured by EQ5DL questionnaires
|
Entry into study, 1 year, and 2 years
|
|
Change in exercise capacity
Time Frame: Entry into study, 1 year, and 2 years
|
Change in exercise capacity measured by treadmill exercise test
|
Entry into study, 1 year, and 2 years
|
|
Follow up events
Time Frame: 1 yea, and 2 years
|
Follow up events defined as death, need for surgery, heart failure symptoms, or valvular disease related hospitalizations
|
1 yea, and 2 years
|
|
Change in degree of myocardial fibrosis
Time Frame: Entry into study, 1 year, and 2 years
|
Change in degree of myocardial fibrosis measured as the percentage left ventricular hyperenhancement and change in mean ECV
|
Entry into study, 1 year, and 2 years
|
Collaborators and Investigators
Sponsor
Sponsor
Study record dates
Study Major Dates
Study Start (Actual)
Study Start
Primary Completion (Anticipated)
Primary Completion
Study Completion (Anticipated)
Study Completion
Study Registration Dates
First Submitted
First Submitted
First Submitted That Met QC Criteria
First Submitted That Met QC Criteria
First Posted (Actual)
First Posted
Study Record Updates
Last Update Posted (Actual)
Last Update Posted
Last Update Submitted That Met QC Criteria
Last Update Submitted That Met QC Criteria
Last Verified
Last Verified
More Information
Terms related to this study
Keywords
Additional Relevant MeSH Terms
Other Study ID Numbers
Other Study ID Numbers
- 1444724
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
Studies a U.S. FDA-regulated device product
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.